New Pill for Mantle Cell Lymphoma After Prior Treatment

Beqalzi (sonrotoclax; Medication Guide pronunciation bee KAHL zee) is an oral B-cell lymphoma 2 (BCL-2) inhibitor. On the USPI, sonrotoclax binds BCL-2, displaces pro-apoptotic proteins, and induces apoptosis in cells that overexpress BCL-2. It is given as a tablet, swallowed whole with a meal and water.

Distinct from venetoclax (fact-only): Sonrotoclax is a separate BCL-2 inhibitor molecule with its own US brand, NDA, dose, 4-week ramp-up, TLS / infection / neutropenia safety story, and labelled MCL indication. Company materials describe Beqalzi as the first BCL-2 inhibitor approved for MCL in the United States. USPI pharmacokinetics: mean terminal half-life 4 to 6 hours, with limited systemic accumulation after repeated dosing. Compare labels with the clinic; the products are not interchangeable by self-switching.

The FDA approved NDA 220711 under accelerated approval on 13 May 2026 (Novel Drug Approvals for 2026 table row 14). Approval letter signed R. Angelo de Claro, MD, Director, Office of Oncologic Diseases, OND/CDER (electronic signature ROMEO A DE CLARO 05/13/2026 10:14:34 AM). NDA dated and received 26 September 2025. Applicant / manufactured for: BeOne Medicines USA, Inc., Pennington, NJ. openFDA: Type 1 new molecular entity; Priority review; Orphan property. Company materials also cite Breakthrough Therapy, Fast Track, and Orphan Drug designations for this MCL indication. The application was not referred to an FDA advisory committee. Dating period on the letter: 24 months from manufacture at 20–25 °C. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) — accelerated-approval postmarketing requirement 4994-1 is a randomized trial of sonrotoclax + zanubrutinib versus placebo + zanubrutinib in R/R MCL, with IRC-assessed progression-free survival as the primary endpoint and overall survival among key secondary endpoints (sponsor timetable on the letter: trial completion 02/2030, final report 09/2030; FDA Ongoing Cancer Accelerated Approvals table lists final-report timing through 9/30/2030). That confirmatory programme is CELESTIAL-RRMCL (NCT06742996), which remains recruiting.

Where this is taking place

Commercial labelled door today: United States — FDA accelerated approval for adults with R/R MCL after ≥2 lines of systemic therapy including a BTK inhibitor. This is a lymphoma / hematology clinic conversation with TLS risk assessment, hydration / anti-hyperuricemic prophylaxis, laboratory monitoring during ramp-up, and a labelled oral course — not a casual retail pickup and not a DIY import.

Outside the United States: China — company US approval materials state Beqalzi / sonrotoclax is also approved in China for R/R MCL and for adult CLL/SLL after prior systemic therapy including a BTK inhibitor; secondary regulatory summaries date conditional NMPA approval to 6 January 2026 (local brand Baiyueda on those summaries). Ask a China-based hematology clinician for the local labelled text and supply path; a US bottle is not a China carton. As of this draft, no confirmed Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, TGA ARTG listing, Swissmedic authorisation, or PMDA/MHLW licence for Beqalzi / sonrotoclax. Company materials note EMA review of the R/R MCL data — that is a review, not an EC marketing authorisation. Do not import on your own.

BGB-11417-201 — NCT05471843 (USPI Study) — Phase 1/2, single-arm, multicenter, open-label. Lead sponsor on ClinicalTrials.gov: BeiGene (BeOne family naming). CT.gov status: ACTIVE, NOT RECRUITING. Actual enrolment 125. Start 5 Sep 2022; actual primary completion 18 Jul 2025; estimated study completion 31 Jan 2027. Countries with listed sites include the United States, Argentina, Belgium, Brazil, Canada, China, France, Germany, Israel, Italy, Poland, Puerto Rico, Spain, Turkey (Türkiye), and the United Kingdom. Canadian site on the record: QeII Health Sciences Centre (Halifax) — trial geography, not a Health Canada licence. Not a new-enrolment path for newly labelled commercial use — the pivotal efficacy population that supports the accelerated label is already enrolled.

CELESTIAL-RRMCL — NCT06742996 (confirmatory) — Phase 3, randomized, double-blind, multicenter. Lead sponsor on ClinicalTrials.gov: BeOne Medicines. CT.gov status: RECRUITING. Estimated enrolment 300. Start 5 Mar 2025; estimated primary completion 31 Aug 2028; estimated study completion 30 Mar 2032. Central contact on the record: Study Director — 1-877-828-5568 / clinicaltrials@beonemed.com (trial operations — not a commercial prescription desk). Countries with listed sites include the United States, Argentina, Australia, Austria, Brazil, China, France, Germany, Italy, Japan, New Zealand, Poland, Puerto Rico, South Korea, Spain, Turkey (Türkiye), and the United Kingdom. No Canadian sites on the API record retrieved for this draft. This confirmatory combination trial is not the same door as labelled US monotherapy Beqalzi for pretreated MCL.

The practical door in the US is a lymphoma-experienced clinician who can confirm prior-line history (including BTK inhibitor exposure), assess TLS risk, arrange hydration / anti-hyperuricemics / chemistry monitoring through the 4-week ramp-up, write labelled 320 mg once daily with food thereafter, and watch infections and blood counts — not treating NCT05471843 as open recruitment, and not treating CELESTIAL-RRMCL as the commercial monotherapy label.

Approval matrix

Access by country

• United States: Ask a lymphoma / hematology clinic about FDA-labelled Beqalzi. Labelled 13 May 2026 (accelerated) for adults with relapsed or refractory MCL after at least two lines of systemic therapy, including a BTK inhibitor. Recommended target dose after ramp-up: 320 mg orally once daily with a meal and water until progression or unacceptable toxicity. Strengths: 1 mg, 5 mg, 20 mg, and 80 mg tablets. Starter pack NDC 72579-015-04; maintenance 80 mg bottle NDC 72579-022-08 (120 tablets) among other pack NDCs on the USPI. Prior authorisation and specialty-pharmacy logistics still apply. No list price or copay dollars in this article. Suspected adverse reactions: BeOne Medicines 1-877-828-5596 or FDA MedWatch 1-800-FDA-1088. Prescribing Information: FDA label PDF / DailyMed. This is US commercial labelled supply, not a DIY import.

• Canada: Beqalzi authorisation not confirmed. BGB-11417-201 lists a Halifax site — trial ≠ Health Canada licence. Do not assume SAP, named-patient, or cross-border mail-order is available or appropriate. Ask the Canadian lymphoma clinic what legal paths exist in Canada when a Beqalzi Canadian label does not yet exist.

• China: Company materials describe China approval for R/R MCL and for CLL/SLL after prior BTK-containing systemic therapy. Ask a local hematology clinician for the China labelled indication, brand, dose, and supply path. A US Beqalzi bottle is not a China carton.

• European Union / United Kingdom / Australia / Japan / other countries with trial sites: Regulator authorisation not confirmed in this draft. EMA review (where applicable) is not a licence. Trial participation or confirmatory CELESTIAL enrolment is not a commercial Beqalzi label.

• If your regulator has not authorised it: do not import on your own. Ask the local lymphoma clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or open CELESTIAL-RRMCL cohorts that actually match eligibility — without treating a US bottle as a foreign carton.

Who is eligible (from the US label)

This is an adult R/R MCL conversation on the USPI — after ≥2 systemic lines including a BTK inhibitor — not a front-line labelled indication and not a paediatric MCL label.

United States (USPI / Medication Guide, revised / issued May 2026):

• Indication: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
• Accelerated approval honesty: Based on response rate and durability of response. Continued approval may be contingent on confirmatory trial(s).
• Recommended dosage: Begin with the 4-week dose ramp-up (Table 1), then 320 mg orally once daily (four 80 mg tablets) with a meal and water until disease progression or unacceptable toxicity.
• Ramp-up (once daily): Week 1 Days 1–3 1 mg, Days 4–7 2 mg; Week 2 Days 1–3 5 mg, Days 4–7 10 mg; Week 3 Days 1–3 20 mg, Days 4–7 40 mg; Week 4 Days 1–3 80 mg, Days 4–7 160 mg; then target 320 mg.
• Swallow tablets whole with food and water; do not break, chew, or crush.
• Missed dose: If missed within 8 hours, take as soon as possible with a meal; if missed by more than 8 hours, skip — do not double. If vomiting after a dose, take the next dose at the usual time the next day.
• TLS prophylaxis: Assess TLS risk; hydrate (Medication Guide: about 6–8 glasses / 1.5–2 L water daily starting 1–2 days before first dose and on dose-increase days); anti-hyperuricemics; correct electrolytes; consider hospitalization for high-risk patients.
• Contraindication: Concomitant strong CYP3A inhibitors at initiation and during the ramp-up phase.
• Pregnancy / contraception: Can cause fetal harm. Verify pregnancy status before start when applicable. Females of reproductive potential: effective contraception during treatment and for 1 week after the last dose. Males with female partners of reproductive potential: effective contraception during treatment and for 1 week after the last dose.
• Lactation: Advise not to breastfeed during treatment and for 1 week after the last dose.
• Fertility: May impair fertility in males and females (animal data); findings described as reversible in animals.
• Pediatrics: Safety and effectiveness not established.
• Geriatrics: Of 115 MCL patients, 64% were ≥65 and 23% were ≥75; higher serious AR rate in ≥65 (42% vs 29% younger); efficacy differences by age not established on the label.
• Renal: No dosage modification recommended for eGFR ≥30 mL/min; severe renal impairment (eGFR <30) not studied.
• Hepatic: No dosage modification recommended for mild or moderate hepatic impairment; severe hepatic impairment not studied.
• Trial context (USPI Study): required prior anti-CD20–based therapy and a BTK inhibitor; excluded CNS lymphoma, prior BCL-2 inhibitor, ECOG >2.

Not labelled on sources confirmed for this draft:

• Children / adolescents for this MCL indication.
• EU, UK, Canadian, Japanese, Australian, or Swiss Beqalzi marketing authorisations (not confirmed here).
• US labelled commercial use in CLL/SLL (China label includes CLL/SLL per company materials — not the US indication).
• Using Beqalzi as a free swap for venetoclax without a clinician reading both labels.
• Treating CELESTIAL-RRMCL combination research as the commercial monotherapy label.

What the pivotal study showed (BGB-11417-201 / USPI)

Use the USPI for a US prescription conversation. Journals and conference abstracts are supportive reading. ORR + DOR supported accelerated approval; PFS confirmatory work continues in CELESTIAL-RRMCL.

BGB-11417-201 — NCT05471843:

• Single-arm, multicenter; efficacy population for the label: 103 adults with R/R MCL who previously received anti-CD20–based therapy and a BTK inhibitor, then Beqalzi 320 mg once daily after ramp-up.
• Major efficacy outcomes: confirmed ORR and DOR by IRC using 2014 Lugano criteria.
• Median age 68 (39–85); 74% male; median 3 prior lines (range 1–8); 89% ≥2 prior lines; all exposed to a covalent or noncovalent BTK inhibitor (most commonly ibrutinib 53%, zanubrutinib 27%, pirtobrutinib 14%).

USPI Table 9 (IRC, N=103):

Company approval materials additionally report CR rate 16% (95% CI 9.1–24.0).

Trial-status honesty: The monotherapy efficacy cohort supports the US accelerated label. CT.gov remains ACTIVE, NOT RECRUITING for BGB-11417-201 because follow-up continues — that is not a door for new commercial starters outside labelled US distribution. CELESTIAL-RRMCL (NCT06742996) is recruiting for confirmatory combination work — not a substitute for reading the US monotherapy label with a clinician.

How it is taken (US label — keep this exact)

Safety (what the label puts first)

Contraindication: Strong CYP3A inhibitors at initiation and during the ramp-up phase (increased TLS risk).

Tumor lysis syndrome: Laboratory or clinical TLS in 7% of 115 MCL patients who followed the recommended ramp-up. Can occur as early as 4 hours after the first dose, at dose increases, or on restart. Assess risk; hydrate; anti-hyperuricemics; monitor chemistries; interrupt and restart per label.

Serious infections: Serious infections 14%; Grade ≥3 17%; fatal 2.6%. Most common Grade ≥3 infection: pneumonia (10%). Monitor; treat promptly; consider prophylaxis per guidelines.

Neutropenia: Grade 3 or 4 neutrophil decrease 18% (Grade 4 6%); febrile neutropenia 1.7%. Monitor CBC; interrupt / reduce / discontinue per label.

Embryo-fetal toxicity: Can cause fetal harm. Contraception windows as above (1 week after last dose for females and for males with partners of reproductive potential).

Most common adverse reactions (≥15% on USPI highlights): pneumonia and fatigue.

Selected Table 7 rates (N=115, ≥10%): pneumonia 16% (Grade 3/4 10%; includes 2.6% fatal pneumonia); fatigue 16%; edema 14%; diarrhea 14%; upper respiratory tract infection 12%; pyrexia 10%; constipation 10%; rash 10%; musculoskeletal pain 10%.

Lab abnormalities (Table 8 highlights): lymphocytes decreased Grade 3–4 29%; neutrophils decreased all-grade 50% / Grade 3–4 18%.

Serious ARs: 37% (pneumonia 10% most frequent ≥2%). Fatal ARs 4.3% (pneumonia 2.6%; sudden death 1.7%). Dose interruption 27%; dose reduction 0.9%; permanent discontinuation 8%.

Drug interactions (high level): Strong CYP3A inhibitors contraindicated at initiation/ramp-up; reduce target dose after ramp-up per Table 5. Avoid moderate CYP3A inhibitors at 1 mg and 2 mg doses; reduce other doses per Table 6. Avoid strong or moderate CYP3A inducers. Medication Guide: avoid grapefruit, Seville oranges, and star fruit.

QTc note (pharmacodynamics): Mean QTc increase 7 ms (upper CI 14 ms) after 320 mg with a low-fat meal — characterized incompletely at higher exposures.

Report suspected adverse reactions to BeOne Medicines 1-877-828-5596 or FDA MedWatch 1-800-FDA-1088.

No boxed warning on the USPI retrieved for this draft. That is not “no risk” — TLS, infections (including fatal pneumonia), neutropenia, and pregnancy are the main labelled safety story.

How to talk to a doctor

Bring the brand, the INN, the NDA / NCT numbers, and the US Prescribing Information if you are in a US clinic. Outside the US, bring honesty that a local Beqalzi label may not exist yet (except where a China label applies).

1. “I am an adult with relapsed or refractory mantle cell lymphoma after ≥2 lines of systemic therapy, including a BTK inhibitor. The FDA gave accelerated approval to Beqalzi (sonrotoclax) on 13 May 2026. Is that labelled for me in this country?”
2. “This is a BCL-2 inhibitor, a separate product from venetoclax. Can we compare this label with my prior therapies?”
3. “The labelled target dose is 320 mg by mouth once daily after a 4-week ramp-up, with food. How will we handle TLS prophylaxis, hydration, and lab monitoring during ramp-up?”
4. “BGB-11417-201 (NCT05471843) showed IRC ORR 52% and median DOR 15.8 months in 103 patients. I understand accelerated approval means PFS confirmatory results (CELESTIAL-RRMCL, NCT06742996) are still required — what does that mean for my care plan?”
5. “Please cover strong CYP3A inhibitors (contraindicated at start/ramp-up), grapefruit / Seville orange / star fruit, and my other medicines.”
6. “Please plan pregnancy testing and contraception during treatment and for 1 week after if I can become pregnant / if I have a partner who can. Advise on breastfeeding rules.”
7. “I will watch for TLS symptoms (nausea, vomiting, muscle cramps, irregular heartbeat, decreased urine), fever / infection, and low blood counts. When should I call, and how often will CBC / chemistries be checked?”
8. “Is prior authorisation started? Who coordinates the starter pack (NDC 72579-015-04) and the 320 mg maintenance supply?”
9. “Ex-US Beqalzi authorisations are mostly not confirmed on the sources we are using (China is a separate local label). I will not import a foreign carton.”
10. “If we are outside the US, what legal options exist — local special-access rules, China local label where applicable, referral, confirmatory-trial eligibility, or waiting — without DIY import?”

Research and regulatory team (from sources only — no invented contacts)

Names and roles as they appear on primary sources — not a clinic directory.

• BeOne Medicines USA, Inc., Pennington, NJ — NDA 220711 applicant; USPI “Manufactured for”; AE line 1-877-828-5596.
• BeiGene — ClinicalTrials.gov lead sponsor for NCT05471843 (BeOne family naming).
• BeOne Medicines — ClinicalTrials.gov lead sponsor / Study Director affiliation for NCT06742996.
• Meghal Vakil, MS, CCRP, RAC — Director, Regulatory Affairs, BeOne Medicines USA; addressee on the NDA approval letter (corporate regulatory contact, not a treating clinic).
• R. Angelo de Claro, MD — Director, Office of Oncologic Diseases, OND/CDER — signed the 13 May 2026 approval letter.
• David Bak — FDA Senior Regulatory Health Project Manager named on the approval letter (agency contact, not a patient hotline).
• Michael Wang, M.D. — Global Principal Investigator; Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center — quoted on the BeOne 13 May 2026 approval press (investigator quote, not a national referral desk).
• Amit Agarwal, M.D., Ph.D. — Chief Medical Officer, Hematology, BeOne Medicines — quoted on the approval press (company leadership, not a clinic).
• Meghan Gutierrez — CEO, Lymphoma Research Foundation — quoted on the approval press (patient-community voice, not a prescribing contact).
• CELESTIAL CT.gov trial contact: clinicaltrials@beonemed.com / 1-877-828-5568 — trial information, not commercial fill.
• Site-level hospital phone numbers are not listed here — ask your own lymphoma clinician. CT.gov overall named personal PIs: not listed on the NCT05471843 / NCT06742996 API records retrieved for this draft (facilities / countries + Study Director org titles).

Canada zoom: Beqalzi not confirmed

There is no retrieved Health Canada Notice of Compliance or DIN for Beqalzi / sonrotoclax on the sources used for this draft. US FDA accelerated approval does not create a Canadian Product Monograph. BGB-11417-201 lists a Halifax research site — that is trial geography, not a licence. CELESTIAL-RRMCL had no Canadian sites on the API record used here. Do not treat cross-border mail-order of a US bottle as the care plan. Ask a Canadian lymphoma / hematology clinician what legal options exist while waiting for any future Canadian Beqalzi decision.

Bottom line

Beqalzi (sonrotoclax) is an FDA-approved oral BCL-2 inhibitor — labelled 13 May 2026 under accelerated approval (NDA 220711) for adults with relapsed or refractory MCL after ≥2 lines of systemic therapy including a BTK inhibitor. Target dose: 320 mg by mouth once daily after a 4-week ramp-up, with food. BGB-11417-201 (NCT05471843) showed IRC ORR 52% and median DOR 15.8 months in 103 patients; PFS confirmatory work continues in CELESTIAL-RRMCL (NCT06742996; PMR 4994-1). Watch TLS, infections (including pneumonia), neutropenia, CYP3A interactions, and pregnancy. US labelled; China has a separate local approval story (company / secondary). Other major regulators not confirmed. EMA review is not a foreign licence. Distinct molecule from venetoclax — compare labels; do not self-swap. The door is a lymphoma clinic writing the US label with ramp-up and TLS prophylaxis — pivotal follow-up is not a new commercial enrolment path, and a recruiting confirmatory combo trial is not the commercial monotherapy carton. Authorized is not funded.

---

Primary sources

1. FDA Novel Drug Approvals for 2026 — Beqalzi / sonrotoclax, approval date 5/13/2026, row 14 — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
2. FDA Ongoing Cancer Accelerated Approvals — Beqalzi (sonrotoclax) row; PMR 4994-1; final-report timing 9/30/2030 — https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
3. FDA Prescribing Information PDF, NDA 220711, label 220711Orig1s000lbl.pdf, Revised 5/2026 — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220711Orig1s000lbl.pdf
4. FDA NDA approval letter, NDA 220711, signed R. Angelo de Claro, MD, 13 May 2026 — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220711Orig1s000ltr.pdf
5. DailyMed BEQALZI (sonrotoclax), setid ff684558-e9cb-46de-a8bf-f4d79093df7a — https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff684558-e9cb-46de-a8bf-f4d79093df7a
6. openFDA Drugs@FDA application NDA220711 (Priority; Orphan; Type 1 NME; BeOne Medicines USA) — https://api.fda.gov/drug/drugsfda.json?search=openfda.brand_name:BEQALZI
7. BeOne Medicines / Business Wire — BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma, 13 May 2026 — https://www.businesswire.com/news/home/20260513542161/en/BeOne-Medicines-BEQALZI-sonrotoclax-Approved-by-U.S.-FDA-as-First-and-Only-BCL2-Inhibitor-for-RR-Mantle-Cell-Lymphoma
8. ClinicalTrials.gov NCT05471843 — BGB-11417-201 — https://clinicaltrials.gov/study/NCT05471843
9. ClinicalTrials.gov NCT06742996 — CELESTIAL-RRMCL — https://clinicaltrials.gov/study/NCT06742996
10. Adis Insight / Figshare — Sonrotoclax: First Approval (China conditional NMPA 6 January 2026; Baiyueda) — https://doi.org/10.6084/m9.figshare.31968387